Source comparison
CJC-1295 No DAC & Ipamorelin: Research Protocol Comparison
Primary Endpoint Plasma GH/IGF-1 response Nitrogen balance, lipolysis markers Body composition, tissue regeneration, metabolic health Acute studies validate peptide activity; chronic studies measure therapeutic relevance Dosing Frequency Single injection 2–3x
This comparison does not assign a generated winner or score.
- Primary Endpoint
- Plasma GH/IGF-1 response
- Nitrogen balance, lipolysis markers
- Body composition, tissue regeneration, metabolic health
- Acute studies validate peptide activity; chronic studies measure therapeutic relevance
- Dosing Frequency
- Single injection
- 2–3x daily subcutaneous
- Sustained protocols required. Single doses produce transient effects only
- Observable Timeline
- GH peaks 60–90 min; IGF-1 rises 6–12 hrs
- Detectable changes by week 2–3
- Significant outcomes by week 8+
- Timeline depends on outcome. Hormone assays differ from physiological endpoints
- Typical Dose Range
- 100–200 mcg each peptide
- 100–300 mcg CJC / 200–300 mcg ipamorelin per dose
- Same dosing, extended duration
- Higher doses do not accelerate chronic outcomes. Duration matters more than dose escalation
- Control Requirements
- Placebo or vehicle injection
- Matched placebo cohort, diet-controlled
- Matched placebo, diet/activity controlled
- Without controls, peptide effects cannot be isolated from baseline GH secretion or environmental variables
- Statistical Power
- N=10–15 sufficient for GH assay
- N=20–30 for intermediate markers
- N=30–50 for body composition endpoints
- Small sample sizes in chronic studies produce underpowered results. Most pilot studies fail here